U.S. Markets closed

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.27+0.58 (+8.67%)
At close: 1:00PM EST
Sign in to post a message.
  • J
    Jason
    yup. the kind of dead money that one day might be $7/share friday close and $17 or .$70 monday open. it's just how these investments go.
  • K
    Kash
    One of the most undervalued stocks of 2020 , LOL at the panic . I can't believe I get to buy it so cheap .
    Bullish
  • M
    Matthew
    Well... there will be a conference in 2 seconds maybe there is some cost savings and a new direction they have decided to move in and that has played into the decision to end the trial as well.
  • d
    dillois
    Wow, at current burn rate, funded through 2023! Rare to see that kind of stability in an early stage biotech.
  • C
    Chuck
    13G filing - Gilead shows 13.9% passive stake in Jounce.
    Bullish
  • C
    Christopher
    I really want to raise my cost basis and buy more. This has great potential.
  • e
    eddypgil
    Way over done. Company has good pipeline and low valuation
  • M
    Matthew
    let's see what earnings have to say
  • Y
    Yoav
    Can someone please explain me in a few words what the decline is due to?
  • W
    WallStreetAdvisor
    8064 partnership is just around the corner. This is one super obvious!

    SELECT trial Phase 2 announcement coming up in few days.

    JTX-8064 can fetch 200-300M cash and 1B milestone payment, as it improves PD1 efficacy dramatically.
  • J
    Jason
    chuck- this is good news right? gild deal went through. 120 million already in jnce bank account. 6.31 per share may be causing angst. but at the time jnce was trading below 5. anyway i view this is really good news.
  • M
    Matthew
    if you are part of the up 50% club right now hold tight to add another digit to that gain!
  • e
    eddypgil
    New 52 week high next week
  • J
    Jason
    jnce market cap appears to be about what it has in cash at this point.
  • M
    Matthew
    Headline to the trade desks: Advisors; post Gilead licensing news low volume reveals cilmb in JNCE stock. That is all
  • M
    Matthew
    i rotated half my position to another stock at when i saw a bear signal at the 20dma. i fully intend to buy near the 50 dma if it gets there. my point is i bet a lot of people will come back in when they see this come down a little just like i did. plus we are approaching earnings/guidance and that plus any news regarding agreements will set the tone.
  • C
    Christopher
    What are your expectations for earnings? I'm in with 627 shares at a cost basis of 9.18 or so.
  • m
    michael
    I don’t own much of this, but it feels good to be in the green with a little cushion. Was going to sell but I think I will wait and see if I can make a decent profit
  • W
    WallStreet
    Merck data should send this to above 14. We are going to clinic by end of this year for 8064. that should take this above 16 or 18.
    meanwhile any partnership , which will be a big one. will take this above 24.
  • W
    WallStreet
    check out Merck data I shared on stocktwits. out of 34 patience 19 had a responce, 2 CRs. 5 failed previous PD1 and ILT4 rherphy plus pd1 worked on them.

    this is going to be big!